Pregnyl/Gestyl 200/400

Verify with FDA CVM →

47 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
47
Total Reports
4
Deaths Reported
850.0%
Death Rate

Active Ingredients

Pregnyl/Gestyl 200/400

Administration Routes

UnknownIntramuscularSubcutaneousTopicalOtherParenteral

Species Affected

Pig 19
Unknown 15
Human 4
Sheep 4
Dog 3
Goat 2

Most Affected Breeds

Unknown 20
Commercial hybrid 9
Pig (unknown) 5
Sheep (unknown) 3
Crossbred Porcine/Pig 2
Goat (unknown) 2
Terrier - Yorkshire 1
Basset - Griffon Vendeen Large 1
Bulldog - French 1
Vietnamese Pot Bellied 1

Most Reported Reactions

INEFFECTIVE, ESTRUS INDUCTION 15
Hyperextension 12
Underfilling, Container 7
Lack of efficacy - NOS 6
Product problem 5
Product Defect, General 5
Expired drug administered 4
Reduced conception rate 4
Underfilling, Vials 4
Underfilling, Package 4
Anoestrus 3
Lack of heat 3

Outcome Breakdown

Outcome Unknown
24 (68.6%)
Recovered/Normal
6 (17.1%)
Euthanized
3 (8.6%)
Ongoing
1 (2.9%)
Died
1 (2.9%)

Data Summary

Metric Value
Total adverse event reports 47
Reports involving death 4
Case-fatality rate (reported events) 850.0%
Distinct species in reports 6
Distinct breeds in reports 12
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Pregnyl/Gestyl 200/400 Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 47 adverse event reports referencing Pregnyl/Gestyl 200/400, including 4 reports in which the animal died — a 850.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Pregnyl/Gestyl 200/400. Reported administration routes include Unknown, Intramuscular, Subcutaneous, Topical. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Pregnyl/Gestyl 200/400 reports are Pig (19 reports), Unknown (15 reports), Human (4 reports), with Pig accounting for the largest share. Within those species, Unknown (20), Commercial hybrid (9), Pig (unknown) (5) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Pregnyl/Gestyl 200/400 are INEFFECTIVE, ESTRUS INDUCTION (15), Hyperextension (12), Underfilling, Container (7), Lack of efficacy - NOS (6). Of the 35 reports with a coded outcome, Outcome Unknown is the leading category at 68.6%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Pregnyl/Gestyl 200/400.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial